BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual WorkshopGlobeNewsWire • Monday
BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual MeetingGlobeNewsWire • 10/20/26
BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroupsProactive Investors • 10/19/26
BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meetingProactive Investors • 10/14/26
BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual MeetingGlobeNewsWire • 10/14/26
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets TranscriptSeeking Alpha • 09/23/26
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid TranscriptSeeking Alpha • 09/15/26
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDGlobeNewsWire • 09/15/26
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long CovidGlobeNewsWire • 09/14/26
BioVie advances Parkinson's Phase 3 development program with FDA engagementProactive Investors • 09/08/26
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDGlobeNewsWire • 08/31/26
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design TranscriptSeeking Alpha • 08/13/26
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterimProactive Investors • 08/06/26
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's DiseaseGlobeNewsWire • 08/06/26
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites TranscriptSeeking Alpha • 06/03/26
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDGlobeNewsWire • 05/26/26